Barcelona, Spain, November 3, 2021 - Minoryx Therapeutics announces that additional data of its Phase 2/3 ADVANCE clinical trial has been presented in a poster presentation by Dr. Fanny Mochel, Associate Professor at Sorbonne University, at the 146th Annual Meeting of the American Neurological Association (ANA) 2021.

Minoryx’s Phase 2/3 ADVANCE clinical trial was a pivotal multicenter, double-blind and placebo-controlled study conducted in the United States and Europe in adult male patients with AMN. The results showed that Minoryx’s therapy leriglitazone reduces the progression of cerebral lesions and, based on plasma biomarkers, modulates neuroinflammation, preserves blood-brain barrier integrity and protects against axonal degeneration. In addition, leriglitazone showed a reduction in the risk of developing progressive cerebral ALD (cALD). These data also support Minoryx’s ongoing NEXUS study, an open-label phase 2 trial assessing leriglitazone in male pediatric patients with early stage cALD.

In the ADVANCE trial, of 116 patients randomized, 77 received leriglitazone and 39 received placebo. Six patients (15.4%) in the placebo group clinically developed progressive cALD compared with no patient (0%) in the leriglitazone group. Plasma biomarker data showed that neurofilament light levels were significantly increased at week 96 in placebo patients with cerebral lesion progression, supportive of a drug effect on axonal degeneration. Treatment with leriglitazone also significantly reduced plasma levels of MMP-9 a marker of blood-brain barrier integrity, and reduced or stabilized plasma levels of inflammatory biomarkers such as MIP-1β, IL-18 and IL-1ra. Furthermore, while at baseline both placebo and leriglitazone groups were well balanced in terms of number of patients with Loes severity score greater than 0, increase in this score was significantly greater in the placebo group.

X-ALD is an orphan inherited neurodegenerative disease. The disease results in very long-chain fatty acids accumulating in plasma and tissues, including the brain, spinal cord and adrenal cortex. The most common form of X-ALD is AMN, which is a chronic disease affecting all male and female X-ALD patients reaching adulthood. There is currently no approved treatment for these patients.

X-ALD patients can also develop an acute form, cerebral ALD (cALD). This results in brain inflammation leading to permanent disability and death within 2-4 years. cALD typically affects boys with an age of onset between 4-8 years. However, up to 60% of adult males with AMN can also develop this aggressive phenotype. For cALD the only currently available treatments are based on Hematopoietic stem cell transplantation (HSCT), but in adult patients this procedure is associated with significant risks and many AMN patients are not eligible for it.

“AMN is a condition with a high unmet medical need with no currently approved treatment. Minoryx’s Phase 2/3 ADVANCE study is the first international and robust study providing evidence of drug effect in this population,” said Marc Martinell, CEO, Minoryx. “Additional analysis of the ADVANCE study data has shown that leriglitazone may provide significant clinical benefits in multiple endpoints related with cerebral lesion progression.”

“There is an urgent need for therapies to treat and prevent cALD, particularly in the adult AMN population where hematopoietic stem cell transplantation has significant limitations,” said Dr. Fanny Mochel “Reducing the risk of developing progressive cALD is vital and holds promise for patients suffering from AMN who currently have no available therapeutic options.”

Leriglitazone has been granted orphan drug status for X-ALD from the FDA and the EMA and fast track and rare pediatric disease designation from the FDA for the treatment of X-ALD. Minoryx is currently under discussions with regulatory authorities for an approval path of leriglitazone for AMN patients.

*For more information, please visit Minoryx website.